SCHEMBL1639504

SCHEMBL1639504

Cc1cnc2ccc(Br)cc2n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
PABPC1 P11940 1/20 0.40
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
PIK3R1 P27986 1/20 0.39
PIK3CA P42336 1/20 0.39
TNF P01375 1/20 0.38
BACE1 P56817 2/20 0.38
CASP3 P42574 1/20 0.38
PTGES O14684 2/20 0.38
CCNB2 O95067 1/20 0.37
CDK1 P06493 1/20 0.37
CCNB1 P14635 1/20 0.37
CDK5 Q00535 1/20 0.37
CDK5R1 Q15078 1/20 0.37
CCNB3 Q8WWL7 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30390906 1.00 HTT (0.41) HTTCYP1A2CYP2C19PABPC1ALDH1A1
SCHEMBL1641255 0.92 PABPC1 (0.44) HTTCYP1A2CYP2C19PABPC1ALDH1A1
SCHEMBL30133942 0.87 HTT (0.38) HTTCYP1A2CYP2C19PABPC1ALDH1A1
SCHEMBL30900062 0.87 HTT (0.38) HTTCYP1A2CYP2C19PABPC1ALDH1A1
SCHEMBL29796578 0.84 CYP1A2 (0.44) HTTCYP1A2ALDH1A1KDM4EMAPT
SCHEMBL22074904 0.84 CYP1A2 (0.44) HTTCYP1A2ALDH1A1KDM4EMAPT
SCHEMBL30578800 0.79 CYP1A2 (0.54) CYP1A2ALDH1A1KDM4EBACE1CCNB2
SCHEMBL29639029 0.79 CYP1A2 (0.54) CYP1A2ALDH1A1KDM4EBACE1CCNB2
SCHEMBL8344116 0.79 CYP1A2 (0.54) CYP1A2ALDH1A1KDM4EBACE1CCNB2
SCHEMBL26919701 0.79 HTT (0.44) HTTCYP1A2CYP2C19PABPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125378-A2 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2026-05-07 US disclosed
EP-4658650-A1 HETEROCYCLIC COMPOUNDS Beone Medicines I GmbH (CH) 2025-12-10 EP disclosed
US-20250353846-A1 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2025-11-20 US disclosed
US-20250333399-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES KHORA SPV 1 LLC (US) 2025-10-30 US disclosed
US-12331039-B2 Inhibitors of fibroblast growth factor receptor kinases KHORA SPV 1, LLC (US) 2025-06-17 US disclosed
CN-119215050-A Application of substituted imidazoquinoxaline compound in preparation of anti-cancer drugs 上海瑛派药业有限公司 2024-12-31 CN disclosed
CN-119119033-A Pyrazolopyridone compounds 百济神州有限公司 2024-12-13 CN disclosed
CN-119080781-A Substituted imidazoquinoxaline compounds and uses thereof 上海瑛派药业有限公司 2024-12-06 CN disclosed
US-20240300951-A1 Pyrazolopyridinone Compounds BEIGENE LTD. (KY) 2024-09-12 US disclosed
CN-114787162-B Substituted imidazoquinoxaline compounds and uses thereof 上海瑛派药业有限公司 2024-09-03 CN disclosed
US-20110098285-A1 BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2011-04-28 US disclosed
WO-2010052448-A2 FUSED PYRAZINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2010-05-14 WO disclosed
US-20090054420-A1 BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2009-02-26 US disclosed
US-7456196-B2 Bicyclic-substituted amines as histamine-3 receptor ligands ABBOTT LABORATORIES (US) 2008-11-25 US disclosed
US-7153889-B2 Bicyclic-substituted amines as histamine-3 receptor ligands ABBOTT LABORATORIES (US) 2006-12-26 US disclosed
US-20060194798-A1 Bicyclic-substituted amines as histamine-3 receptor ligands ABBVIE INC. 2006-08-31 US disclosed
EP-1569637-A1 BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS Abbott Laboratories (US) 2005-09-07 EP disclosed
US-20040152704-A1 Bicyclic-substituted amines as histamine-3 receptor ligands ABBVIE INC. 2004-08-05 US disclosed
WO-2004043458-A1 BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2004-05-27 WO disclosed
US-20040092521-A1 Bicyclic-substituted amines as histamine-3 receptor ligands ABBOTT LABORATORIES 2004-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125378-A2 Heterocyclic Compounds NFATC1, CD4, MALT1 HTT 3797/4885CYP1A2 656/4885CYP2C19 1667/4885
US-20110098285-A1 BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS HRH3, HRH4, HRH2 HTT 1701/4885CYP1A2 1051/4885CYP2C19 821/4885
US-20060194798-A1 Bicyclic-substituted amines as histamine-3 receptor ligands HRH3, HRH4, HRH2 HTT 1701/4885CYP1A2 1051/4885CYP2C19 821/4885
US-12331039-B2 Inhibitors of fibroblast growth factor receptor kinases FGFR1, FGFR2, FGFR3 HTT 2931/4885CYP1A2 4269/4885CYP2C19 4111/4885
US-20250333399-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES FGFR1, FGFR2, FGFR3 HTT 2931/4885CYP1A2 4269/4885CYP2C19 4111/4885
US-20250353846-A1 Heterocyclic Compounds NFATC1, CD4, ACIN1 HTT 4222/4885CYP1A2 2185/4885CYP2C19 2951/4885
US-20240300951-A1 Pyrazolopyridinone Compounds NFATC1, CD4, PBK HTT 4803/4885CYP1A2 2016/4885CYP2C19 2456/4885
US-20090054420-A1 BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS HRH3, HRH4, HRH2 HTT 1701/4885CYP1A2 1051/4885CYP2C19 821/4885
US-20040092521-A1 Bicyclic-substituted amines as histamine-3 receptor ligands HRH3, HRH4, HRH1 HTT 2298/4885CYP1A2 1015/4885CYP2C19 1062/4885
US-20040152704-A1 Bicyclic-substituted amines as histamine-3 receptor ligands HRH3, HRH4, HRH1 HTT 2308/4885CYP1A2 838/4885CYP2C19 799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.